Cancer

Cancer Genetics, Inc. was a leader in enabling precision medicine in oncology through specialized diagnostic services and drug discovery support. The company focused on developing and commercializing proprietary genomic tests for various cancers, including hematological malignancies and solid tumors. Their services catered to both clinicians for patient management and pharmaceutical companies for clinical trial enrichment and biomarker discovery. In 2021, the company underwent a significant transformation by merging with StemoniX to form Vyant Bio, shifting its focus toward AI-driven drug discovery and human-first organoid models.